Today's Hours: 8:00am - 8:00pm

Search

Filter Applied Clear All

Did You Mean:

Search Results

  • Book
    Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano, editors.
    Contents:
    Intro
    Foreword
    Preface
    Acknowledgments
    Contents
    Contributors
    1: Background: Immunology and Cancer
    References
    2: Available Immunotherapy Drugs in Oncology
    Anti-PD-1 Agents
    Pembrolizumab
    Nivolumab
    Anti-PD-L1 Agents
    Atezolizumab
    Durvalumab
    Avelumab
    Anti-CTLA4 Agents
    Ipilimumab
    References
    3: Immunotherapy Adverse Events
    Introduction
    Myocarditis
    Noninflammatory Myocardial Dysfunction
    Arrhythmias
    Pericardial Disease
    Vasculitis
    Myocardial Infarction
    References
    4: Pathophysiology of Cardiac Toxicity
    Pathophysiology of Cardiac Toxicity: An Overview
    Cardiac Dysfunction and Heart Failure
    Vascular Disease
    Arrhythmias
    Pericardial and Valvular Disease
    References
    5: Cardiac Risk Factors for Immunotherapy
    Why Evaluate the Cardiovascular Risk in Oncological Patients Who Have Undergone Immunotherapy?
    How to Quantify Cardiovascular Risk?
    Experimental Preventive Strategies for Immune Checkpoint Inhibitor (ICI)-Induced Cardiotoxicity: Evidence and Perspectives
    References
    6: Diagnostic Methods of Cardiac Immunotherapy Damaging
    Introduction
    Clinical and Electrocardiographic Evaluation
    Echocardiography
    Myocardial Deformation Imaging
    Nuclear Imaging and Cardiac Magnetic Resonance
    Role of Biomarkers
    Role of Endomyocardial Biopsy
    Diagnostic Approach
    Conclusion
    References
    7: Biomarkers of Early Cardiotoxicity
    Introduction
    Cardiac Troponins
    Brain Natriuretic Peptides
    New Emerging Biomarkers
    Conclusion
    References
    8: Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist
    Introduction
    Atherosclerosis and Cardiovascular Events
    Myocarditis and Heart Failure
    Clinical Presentation
    Diagnosis
    Management
    ICI-Associated Pericarditis
    Diagnosis
    Management. Takotsubo Syndrome
    Arrhythmias
    Management
    Immunotherapy-Associated Vasculitis
    Immunotherapy-Associated Thromboembolism
    Screening and Surveillance
    Conclusion
    References
    9: Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist
    Introduction
    Mechanisms of Action of Cardiovascular ICI Adverse Events
    Myocarditis
    Epidemiology
    Physiopathology
    Clinical Presentation
    Laboratory and Imaging Findings
    Diagnosis and Management
    Pericarditis
    Epidemiology
    Pathophysiology
    Clinical Presentation
    Diagnosis
    Management
    Acute Coronary Syndrome (ACS) and Myocardial Infarction (MI)
    Epidemiology
    Physiopathology
    Clinical Presentation
    Diagnosis
    Management
    Takotsubo Cardiomyopathy
    Epidemiology
    Pathophysiology
    Clinical Presentation
    Diagnosis
    Management
    Dysrhythmias
    Epidemiology
    Pathophysiology
    Diagnosis
    Management
    Vasculitis
    Epidemiology
    Pathophysiology
    Clinical Presentation
    Diagnosis
    Management
    Cardiotoxicity Related to New Immunotherapy (CAR T Cell)
    Epidemiology
    Pathophysiology
    Diagnosis
    Management
    Baseline Assessment and General Principle of Management for Cardiovascular IRAE
    Conclusion
    References
    10: Future Perspectives
    Introduction
    Basic and Translational Research
    Clinical Research
    Education and Training
    Service Organization and Provision
    References
    Index.
    Digital Access Springer 2022